



Eisai Co., Ltd.

4-6-10 Koishikawa, Bunkyo-ku, Tokyo 112-8088, Japan

Phone: 03-3817-5120

Fax: 03-3811-3077

Eisai is a Human Health Care Corporation striving for innovative solutions in prevention, cure and care for the health and well-being of people worldwide. We combine our talents to understand and meet the needs of patients and their families to enhance the quality of life.

FOR IMMEDIATE RELEASE

No. 07-51

December 18, 2007

Eisai Co., Ltd.

**Eisai Enters into In-licensing Agreement with Minophagen Pharmaceutical
for Liver Disease/Allergic Disease Agents
*Stronger Neo-Minophagen[®] C and Glycyron[®] Tablets***

Eisai Co., Ltd. (Headquarters: Tokyo, President and CEO: Haruo Naito) signed an in-licensing agreement with Minophagen Pharmaceutical Co., Ltd. (Headquarters: Tokyo, President and CEO: Kyozo Utsunomiya) for liver disease/allergic disease agents *Stronger Neo-Minophagen[®] C* and *Glycyron[®] Tablets* on December 18, 2007.

With this agreement, Eisai will assume exclusive rights for development and marketing of these products in Japan and in the Euro-Asia countries and region where the products are yet to be sold.*¹ For China and the Euro-Asia countries and region where the products are currently sold*², Eisai will assume exclusive first negotiation rights, with exclusive marketing rights in China upon termination of the existing agreement between Minophagen Pharmaceutical and its current local marketing partner. The companies expect to transfer the marketing activities to Eisai in China on April 1, 2009. In Japan, transfer of the marketing activities for *Stronger Neo-Minophagen[®] C* and *Glycyron[®] Tablets* are expected to take place on April 1, 2008 and October 1, 2008, respectively.

It has been reported that about 170 million people in China are affected with viral hepatitis and 70 percent of these cases are hepatitis B, which is treated by antiviral therapy and immunotherapy including interferon or hepato-protector therapy. Currently, Eisai is developing *clevidine*, an antiviral agent for viral hepatitis B that has been licensed by Bukwang (Korea), and by introducing the two agents announced today to Eisai's product

areas. In Japan, Eisai markets a proton pump inhibitor *Pariet*[®] and gastritis/gastric ulcer treatment *Selbex*[®].

With this agreement, Eisai can enhance its product lineup for the gastrointestinal disorders area that is available in countries in Asia including Japan and China, and thereby make further contributions to increase the benefits to patients and their families.

*¹The Euro-Asia countries and region where the products are yet to be sold:
Singapore, Philippines, Hong Kong, Malaysia, Thailand, Vietnam, Myanmar, Cambodia, Laos, Brunei, Australia, the Middle East Countries (Jordan, Saudi Arabia, Kuwait, UAE, Yemen), Russia.

*²The Euro-Asia countries and region where the products are currently sold:
China, South Korea, Taiwan, Indonesia, India, Mongolia, Uzbekistan, Egypt

<Notes to Editor>

About *Stronger Neo-Minophagen*[®] C

Product Name:

Stronger Neo-Minophagen[®] C Injection 20mL

Stronger Neo-Minophagen[®] C Injection 5mL

Stronger Neo-Minophagen[®] C Injection P 20mL (plastic ampoule)

Active Ingredients: Monoammonium glycyrrhizinate, glycine (JP), L-cysteine hydrochloride (compounding ingredient)

Applied Indication: Eczema or dermatitis, urticaria, pruritus, drug eruption or toxicoderma, stomatitis, infant strophulus, phlycten, improvement of abnormal hepatic function in chronic hepatic disease.

Dosage and Administration: The usual adult dosage for intravenous use is from 5 to 20mL once a day. The dosage may be adjusted depending on the patient's age and symptoms. For chronic hepatic disease, the daily dosage is from 40 to 60mL once a day by intravenous injection or intravenous drip infusion. The dosage may be adjusted depending on the patient's age and symptoms. If an increased dosage is required, the daily dosage should be kept within the limit of 100mL.

About *Glycyron*[®] Tablets

Product Name: *Glycyron*[®] Tablets

Active Ingredients: Monoammonium glycyrrhizinate, glycine (JP), DL-Methionine (compounding ingredient)

Applied Indication: Improvement of abnormal hepatic function in chronic hepatic disease. Eczema or dermatitis, infant strophulus, alopecia, stomatitis.

Dosage and Administration: Usually, between 2 and 3 tablets once for adults and 1 tablet once for children are orally administered after meal for 3 times a day. The dosage may be adjusted depending on the patient's age and symptoms.